There's so much talk about taking GLP-1 these days. But how does our bodies' own GLP-1 work? And how do you know if your GLP-1 levels are suboptimal? I dig into this very subject as well as how to restore your body's own GLP-1 function.

I also uncover the health implications - particularly blood sugar dysregulation - of low GLP-1 and how GLP-1 function is often the very first domino to fall on the path to diabetes.

I first discussed GLP-1 back in early 2020, before semaglutide was widely available on the market as a weight-loss drug, in an episode titled Blood Sugar Physiology 101. Listen to it here for a detailed explanation of the body's Phase 1 insulin response and its relationship to GLP-1.

In this episode, I give my take on GLP-1 analogs (Ozempic, Mounjaro, etc.). I talk about the benefits, the potential risks that are rarely spoken about and the likely long-term limitations. I get into how these compounds differ from the GLP-1 we make on our own as well as ways to leverage that natural secretion for health benefits. I also dispel the notion that the "natural" GLP-1 stimulators are even remotely on par with the drugs on the market.

BioHarvest Sciences CEO Ilan Sobel and Chief Medical Officer Dr. Brian Cornblatt join the show to talk about how BioHarvest Sciences has hacked all of the sustainability and logistical issues that traditionally come with manufacturing plant-based compounds. They discuss the groundbreaking process by which - through its patented technology – BioHarvest Sciences is able to essentially supercharge the compound within the plant that has the most scientifically-backed therapeutic efficacy, all without chemically altering the molecule.

BioHarvest Sciences has figured out how to properly get those healing compounds into the blood stream, into our cells, and into our tissues in an ingenious way - again, without chemically altering the molecule AT ALL. Most importantly, they put enormous amounts of resources into research and development so that their claims are not just theoretical but actually backed by clinical data. Plus, they join the show on an exciting day as BioHarvest Sciences began trading on the NASDAQ.

2:57 – Ilan Sobel’s story and the ethos of BioHarvest Sciences

10:18 – BioHarvest’s patented technology, and how it leverages the most therapeutically efficacious part of the plant and maximizes solubility in a way no other company is able to

21:25 – VINIA’s capacity to potentiate the ability of other supplements to enter the cells through increased blood flow

25:25 – VINIA’s achievement of 82% solubility (proven through clinical data) vs. the 1% solubility of ALL other brands

26:35 – Twelve hours of sustained levels with two peaks (proven by blood testing) vs. twenty minutes for ALL other brands

28:50 – Breaking down the math of how much of piceid resveratrol actually reaches the blood stream as compared to cis and trans (generic) resveratrol

34:20 – The exquisite pharmacokinetics (how a compound gets absorbed and broken down) of VINIA, and the science behind how BioHarvest was able to achieve what no other company has

38:31 – Future plans for BioHarvest to create more products and compounds using their patented technology

41:00 – BioHarvest’s leveraging of the powerful verbascoside molecule for therapeutic purposes within the olive that no one has been able to achieve yet

43:00 – CEO Ilan Sobel reveals BioHarvest’s future plans to partner with nutraceutical, pharmaceutical and cosmetic companies

47:46 – There are 140 drugs that use botanically-based active pharmaceutical ingredients (API). This comes with challenges similar to those of nutraceuticals. BioHarvest’s plans to solve this problem with their patented technology

54:32 – Timeline to produce a product from start to finish (including the research and development). Cost for a company to have BioHarvest create a product, which includes owning the patent

57:43 – Cellular detox and VINIA’s role

59:50 - Dr. Cornblatt breaks down how unique and groundbreaking the soon-to-be-released olive-based product will be

1:03 - CEO Ilan Sobel makes his first public announcement about

BioHarvest Sciences’ debut on the NASDAQ (ticker: BHST)

bioharvest.com

Vinia.com